GLP-1 drugs are revolutionizing the treatment of obesity and diabetes. Here's what to know about investing in GLP-1 stocks.

GLP-1 medications such as Wegovy, Mounjaro and Ozempic helped drive a 9% year-over-year increase in U.S. prescription dispensing revenue, which reached $683 billion in 2024.  A separate report found ...

Discover how GLP-1 drugs are driving demand for new supplements. Insights from Vitafoods Europe 2025 reveal how the industry ...

Gut‑hormone incretins (e.g., GLP‑1 agonists) are the fastest growing segment, forecast to expand at a 33.15% CAGR through ...

Ozempic is an FDA-approved medication for people with type 2 diabetes. It’s often prescribed off-label for weight loss — that ...

Oprah Winfrey and Elon Musk endorsed it. And though Indian celebrities haven’t yet admitted to their use, the mystery ...

Ozempic and Mounjaro's side effects have a few similar side effects as the NHS plans to rollout the jab for weight loss ...

More than a dozen lawsuits filed in New York and New Jersey claim that weight-loss drugs like Wegovy and Ozempic caused ...

LLY's $1.3 billion Verve deal marks its third M&A in 2025 as it pushes to diversify across cardiovascular, neuro and cancer ...

Eye Surgeon, LASIK specialist, Retina Specialist, and Director, Surya Eye Hospital, sheds light on India’s burgeoning interest in diabetes medication like Ozempic, Wegovy etc, highlighting both opport ...

A federal judge in Texas has upheld the FDA’s decision to remove GLP-1 drugs, including Novo Nordisk’s Ozempic and Wegovy, from its drug shortage list, rejecting a bid by compounding pharmacies to ...

Fifty years of outstanding neuroscience research studies have revealed many secrets of how drugs of abuse affect and change ...